Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer
- PMID: 40083522
- PMCID: PMC11898386
- DOI: 10.21037/jtd-24-1789
Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer
Keywords: Anti-LAG3 antibody; neoadjuvant immunotherapy; resectable non-small cell lung cancer (resectable NSCLC).
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-24-1789/coif). The authors have no conflicts of interest to declare.
Comment on
-
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial.Nat Med. 2024 Jun;30(6):1602-1611. doi: 10.1038/s41591-024-02965-0. Epub 2024 Apr 30. Nat Med. 2024. PMID: 38689060 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources